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Cardiac zygomycosis can be a critical condition with sudden onset of severe congestive heart failure followed by severe
hemodynamic deterioration. We report a fatal course of disseminated fungal infection with a massive intra-atrial thrombosis
caused by a zygomycete, in a five year old boy treated for acute lymphoblastic leukaemia. In addition, we discuss the literature
concerning infections caused by zygomycetes involving the heart. Prognosis is poor. A high index of suspicion and an aggressive
diagnostic and therapeutic approach with the prompt start of preemptive antifungal therapy are key factors to improve outcome.
1. Introduction
Zygomycosis is an opportunistic infection caused by fungi of
the class Zygomycetes [1, 2]. It is transmitted by inhalation,
via a variety of percutaneous routes, or by ingestion of
spores, with rhinocerebral and pulmonary diseases being
the most common manifestation. Invasive zygomycosis is
associated with angioinvasive disease, leading to thrombosis
and infarction of involved tissues. The Zygomycota are
generally characterised by formation of wide ribbon-like
aseptate hyaline hyphae and their sexual reproduction with
formation of zygospores [2].
In hematologic neutropenic patients zygomycosis is fre-
quently characterised by disseminated disease and a rapidly
fatal course. One of the organs that can be infected is the
heart. A review of autopsy findings in 60 patients, with
various underlying conditions (cardiac surgery, neoplasia,
renal failure, intravenous drug use) and cardiac fungal
infections reported the discovery of a zygomycete in 12% of
cases [3]. Acute fulminant cardiac zygomycosis is a critical
clinical condition with sudden onset of severe congestive
heart failure followed by severe hemodynamic deterioration.
We report a fatal course of disseminated fungal infection
with cardiac involvement caused by a zygomycete in a five
year old boy treated for acute lymphoblastic leukaemia
(ALL). Paediatric ALL patients are considered to have a
low risk for developing invasive mould infections. Persistent
signs of infection in these patients without a causative agent
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should not take for granted but instead extensive and invasive
diagnostic procedures should be performed to be able to
target antimicrobial therapy.
2. Case Presentation
A five year old boy, diagnosed at the age of four with an ALL
without central nervous system involvement or unfavourable
cytogenetic features, presented with a history of fever,
neutropenia and a painful right leg since four days and a right
lower lobe consolidation with unilateral pleural eﬀusion
on chest X-ray. At that time he was treated for one year
according to Dutch Childhood Oncology Group (DCOG)
ALL-10 intermediate risk protocol. Due to persisting fever
after 4 days of broad-spectrum antibiotics (ceftazidime and
teicoplanin), the negative blood cultures and the abnormal
findings on chest radiography, the patient was admitted to
our hospital.
Physical examination at this time revealed no abnormal
cardiac sounds, no abnormal breathing sounds, no hepatic
or splenic enlargement, no lymphadenopathy and no signs
of inflammation of the right leg. Laboratory studies showed
a haemoglobin value of 6.3 mmol/l (after blood transfusion)
and a leuco- and thrombocytopenia (leucocytes 0.6 × 109/l;
thrombocytes 50 × 109/l). Blood chemistry showed an
elevated C-reactive protein (CRP 145 mg/l).
Additional diagnostic studies to detect a causative agent
were done. Blood cultures taken were repeatedly negative for
bacteria and fungi. Urine culture and faeces were negative
for fungal pathogens. The multiple sputum cultures taken
did not reveal any microorganisms. Cultures of both pleural
fluid obtained by transthoracic puncture and broncho-
alveolar lavage (BAL) were negative for viral, bacterial and
fungal agents. Aspergillus-antigen (galactomannan) was not
detected in multiple plasma samples, pleural fluid and
BAL fluid. Bone marrow aspirate to rule out a relapse
of his leukaemia showed no malignant cells and cultures
for bacteria and mycobacteria were negative. Urine tested
negative for Legionella antigen. Ciprofloxacin was added to
the antimicrobial therapy, to cover atypical causative agents
of pneumonia. Empiric anti-fungal therapy was not initiated
because of the stable condition of the patient and the negative
test results at that moment.
Despite broad-spectrum antibiotic treatment (ceftazid-
ime, teicoplanin and addition of ciprofloxacin for two days),
fever persisted although the clinical condition remained
stable. After 7 days, the developed a hepatomegaly and
blood tests results showed still a pancytopenia, an elevated
CRP (192 mg/l) and increased liver enzymes. Ultrasound
examination of the abdomen confirmed the hepatomegaly
without any focal lesions which might have been suggestive
for fungal infection.
On day 10 he was transferred to the paediatric intensive
care unit (PICU) of our hospital because of progressive
respiratory distress and signs of a capillary leakage syndrome.
At this time, the urine and faeces cultures became positive for
Candida glabrata, while one out of many sputum samples
grew Aspergillus fumigatus. Physical examination at this
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Figure 1: Ultrasound of the heart showing a round left intra-atrial
tumour mass, compromising almost the whole left atrium.
time showed a pale, moaning boy in respiratory distress
needing supplementary oxygen via a non-rebreathing mask.
On the nail of digit III of the left foot and on the soles of
both feet small vasculitis-like lesions were noticed. Because
of imminent respiratory failure the patient was intubated
and artificial ventilated. Chest X-ray showed the known
consolidation in the right lower lobe, but also pulmonary
oedema with haziness of the perihilar regions. Transoe-
sophageal ultrasound examination of the heart showed
hypocontractility, with a round left intra-atrial tumour mass,
compromising almost the whole left atrium (Figure 1). Sus-
picion of a fungal mass or infected thrombus together with
the recovery of fungal pathogens in urine, faeces and sputum,
led to the initiation of antifungal therapy with liposomal
amphotericin B. Progressive hemodynamic failure developed
without an eﬀect of high-dose inotropic medication and the
clinical condition of the patient deteriorated fast. Several
hours after admission to the PICU the patient died.
3. Autopsy Findings
Autopsy revealed zygomycosis with septic embolisms in
almost all organs. The most striking lesion was a thrombus
in the left atrium of the heart. It was firm, grey-white of
colour and had a diameter of 5 cm. It was confirmed to
the right pulmonary vein and reached towards the mitralic
valve. The microscopic findings showed a great amount of
fungal hyphae embedded in a fibrin-rich medium (Figure 2).
In addition some coronary arteries were filled with septic
emboli and had led to multifocal necrosis of the heart
muscle. The right lung was doubled in weight with a severe
damaged right middle lobe. Microscopically, the lobe was
totally ischemic, with haemorrhage and oedema. It was
caused by several septic embolisms in the medium-sized and
minor vessels where the fungus invaded the arterial wall and
penetrated into the interstitial tissue.
The diagnosis of cardiac zygomycosis with septic
embolisms was based on the morphology of the hyphae
found in almost all the organs. The hyphae were typically
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Figure 2: Histology of the intracardial mass showing a great
amount of fungal hyphae, characterised by irregular wide, non-
septated hyphae with right angle branching, consistent with
zygomycetes (Grocot stain, magnification 40x).
irregularly wide, non-septated and showed frequent right
angle branching. At autopsy tissue samples from liver,
spleen and blood were taken but zygomycetes were not
recovered. Unfortunately, no cultures were obtained from the
right lung, heart and intracardial mass. Post-mortem blood
cultures were positive for C. glabrata.
4. Discussion
In patients with haematological malignancies, zygomycosis
is frequently characterised by disseminated disease and a
rapidly fatal course. Although a reduction in mortality has
been observed recently, the mortality rate still remains high
(70%) [4]. Outcome varies as a function of the underlying
condition (mortality rate up to 66% in malignancy), site
of infection (mortality rate up to 96% in disseminated
disease) and use of antifungal therapy (survival in 70%
of patients treated with antifungal therapy and surgery in
contrast to 3% in patients that were not treated) [5]. A
recent study reports an overall mortality of zygomycosis in
solid organ transplant recipients of 49%, with disseminated
and rhinocerebral zygomycosis having the poorest prognosis.
Surgery combined with amphotericin B (especially the
liposomal formulation) showed to be associated with a better
outcome [6]. The high mortality rate can be explained
partly by diagnostic diﬃculties. In neutropenic patients ante
mortem diagnosis is uncommon because blood cultures
are seldom positive and the diagnostic yield of sputum
cultures and bronchial washings is limited. Furthermore,
there are currently no biological markers available that detect
zygomycetes. Nosari et al. obtained a diagnosis in adults in
vivo only by invasive procedures, like biopsy or surgery [7].
We conducted a literature search and identified forty-
six cases of zygomycosis with cardiac involvement reported
in English-written literature until 2009 [6, 8–41], including
five children aged 2, 8, 9, 13 and 14 years [10, 20, 36, 40].
Underlying disorders were hematological/oncological in 19
patients, including 3 children. Development of intra-cardiac
thrombi occurred in 14 cases. The overall mortality in
this patient group was 89% (41 of 46 cases). In the five
patients who survived zygomycosis with cardiac involve-
ment, zygomycosis was restricted to the heart, all went
through invasive diagnostic procedures and intensive treat-
ment including the combination of surgery and antifungal
therapy [25, 29, 34, 36, 40]. The pathogenesis is not clear
in our patient. Autopsy findings showed infected pulmonary
vasculature, and no evidence for pneumonia. The infected
intra-cardiac tumour mass may have originated from a
cardiac valve. Children with congenital heart defects, with
surgery using vascular patches and grafts, or patients with
valvular disease, with intravenous devices and antibiotic use,
are at greater risk for a fungal endocarditis [42, 43]. Our
patient had a vascular line in situ with its tip lying in the
right atrium. Perhaps this could have been the porte d’entre´e,
as recent studies showed a lack of concordance between site
of endothelial damage and localisation of fungal endocarditis
[44].
More extensive diagnostic procedures could have resulted
in earlier identification of the causative agents. Nosari et
al. found prompt chest CT scan helpful (in 7/13 adult
patients) in diagnosing filamentous fungal infections [7]. In
our patient, a CT-thorax was not performed, because the
chest X-ray showed very clearly the presence of a pulmonary
infiltrate. Retrospectively, a lung biopsy should have been
performed after obtaining the negative results of the pleural
and BAL fluid examinations. Lass-Flo¨rl and her colleagues
showed that CT-guided lung biopsy specimens provided
reliable tools for diagnosing invasive fungal infections [45].
Especially the performance of the calcofluor white staining
to diﬀerentiate between septate and unseptate hyphae helped
guide decisions regarding adequate therapy.
It is questionable if there was a reason to perform at an
earlier stage a cardiac ultrasound. An intra-cardiac tumour
mass caused by fungal infection is rare and has a low rate
of suspicion. In addition, no abnormal cardiac sounds were
heard on physical examination.
With the availability of a wider arsenal of antifungal
agents and the changing epidemiology of fungal patho-
gens that cause invasive fungal disease, the importance
of identification of the infecting fungal pathogen has
increased. Voriconazole, being first-line treatment for inva-
sive aspergillosis, the most common encountered invasive fil-
amentous fungal infection in our hospital, has no activity
against Zygomycetes [46–48], neither has caspofungin [49].
Lipid formulations of amphotericin B remain the gold stan-
dard in the treatment of mucormycosis [2, 7]. Posaconazole,
a new triazole antifungal, has potential benefits for patients
with mucormycosis. Is has shown in vitro activity against
zygomycetes [49–51] as well as in vivo eﬀectiveness [52].
By reviewing the literature, only those patients undergoing
intensive treatment, with a combination of surgery and
amphotericin B (with or without other antifungal agents),
survived.
Retrospectively, this case report illustrates two important
aspects of diagnosing and treating invasive fungal infections
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in immunocompromised patients. First, extensive eﬀorts
should be made to localise the infection and its extensiveness,
followed by invasive procedures to detect the causative fun-
gus. Second, if moulds are suspected and no signs of invasive
aspergillosis (i.e. positive galactomannan test, septate hyphae
in tissue) are present, one should reconsider if voriconazole
should be the first choice treatment. As demonstrated in this
case report, lipid formulations of amphotericin B should be
the first choice to cover a broader range of fungal pathogens.
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